RESCUE: Discontinuation of GLP-1
Reason given: Business decision
Key facts
- Where
- Miami, United StatesSee the site
Where in United States
- BariendoMiami, United StatesNo longer taking part
Trial details
- Who runs it
- Boston Scientific Corporation
- Trial code
- NCT07190794
- Record updated
- 24 July 2026
- Original description
This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.Read full original descriptionShow less
Evaluation of Endoscopic Sleeve Gastroplasty (ESG) as an Alternative Weight Loss Strategy for Patients With Obesity Discontinuing GLP-1 Receptor Agonists Due to Intolerance or Ineffectiveness: A Retrospective Study
This study is designed to compare weight loss outcomes and safety of ESG versus lifestyle modification in patients with obesity who discontinued GLP-1 therapy due to intolerance or suboptimal weight loss.
Inclusion: Adults (≥ 18 years); BMI ≥30 kg/m² and ≤ 50 kg/m2; Discontinued GLP-1 therapy for weight loss (semaglutide and tirzepatide only) for intolerance or suboptimal weight loss (<5% TBWL after 3 months at maximally tolerated dose); Initiation of weight loss management no earlier than August 2021; Completed 1-year follow-up for weight loss management (ESG and lifestyle modification or lifestyle modification alone) following initiation of weight loss treatment; Completed at least two interim visits for weight loss management from 1, 3, 6, through 9 months following initiation of weight loss treatment.
Exclusion: Had bariatric surgery or an endoscopic procedure for weight loss treatment other than ESG with OverStitch™ or OverStitch NXT™ within 1 year of starting weight loss management; Had an additional endoscopic treatment performed prior to or at the time of the ESG procedure that could influence weight loss results; Had another weight loss treatment during the 1-year follow-up reported during this study. Weight loss treatment includes but is not limited to appetite suppressants, anti-obesity medications, plastic surgery or body contouring procedures; History of GLP-1 medication for a reason other than weight management; Missing data regarding GLP-1 treatment history, including weight before GLP-1 treatment and at discontinuation, and discontinuation reason; Pregnancy during the 1 year following initiation of weight loss management.